The table below shows NEUROCRINE BIOSCIENCES INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$782.70M
$595.40M
$389.90M
$339.40M
$256.50M
$228.50M
Capital expenditure
$34.00M
$38.20M
$28.30M
$16.50M
$23.40M
$10.90M
Investing cash flow
-$264.40M
-$126.80M
-$467.10M
-$177.10M
-$130.20M
$4.10M
Dividends paid
-
-
-
-
-
-
NBIX operating cash flow (10-K history)
NEUROCRINE BIOSCIENCES INC reported operating cash flow of $782.70M for fiscal year 2025. That is up 31.5% from $595.40M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$106.18M (FY 2016) to $782.70M. Figures come from the company's audited annual reports as filed with the SEC.
